HDL Metabolism and Atheroprotection. Predictive Value of Lipid Transfers

Advances in Clinical Chemistry

Volumn 65, Issue , 2014, Pages 1-41

  Maranhão, Raul C ^a   Freitas, Fatima R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cholesterol; Cholesteryl ester transfer protein; Emulsions; High density lipoprotein; Lipid nanoparticles; Lipid transfer; Phospholipid transfer protein; Phospholipids; Triglycerides; Unesterified cholesterol

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN;

ANIMAL; ARTICLE; ATHEROSCLEROSIS; DRUG ANTAGONISM; HUMAN; LIPID METABOLISM; METABOLISM; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL;

EID: 84901200882     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800141-7.00001-2     Document Type: Chapter

References (190)

1. Hagerman J.S., Gould R.G. The in vitro interchange of cholesterol between plasma and red cells. Proc. Soc. Exp. Biol. Med. 1951, 78:329-332.
2. Rehnborg C.S., Nichols A.V. The fate of cholesteryl esters in human serum incubated in vitro at 38 degrees. Biochim. Biophys. Acta 1964, 84:596-603.
3. Zilversmit D.B., Hughes L.B., Balmer J. Stimulation of cholesterol ester exchange by lipoprotein-free rabbit plasma. Biochim. Biophys. Acta 1975, 409:393-398.
4. Pattnaik N.M., Montes A., Hughes L.B., Zilversmit D.B. Cholesteryl ester exchange protein in human plasma isolation and characterization. Biochim. Biophys. Acta 1978, 530:428-438.
5. Ihm J., Harmony J.A., Ellsworth J., Jackson R.L. Simultaneous transfer of cholesteryl ester and phospholipid by protein(s) isolated from human lipoprotein-free plasma. Biochem. Biophys. Res. Commun. 1980, 93:1114-1120.
6. Barter P.J., Rye K.A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 2012, 53:1755-1766.
7. Rao R., Albers J.J., Wolfbauer G., Pownall H.J. Molecular and macromolecular specificity of human plasma phospholipid transfer protein. Biochemistry 1997, 36:3645-3653.
8. Barter P.J., Kastelein J.J. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J. Am. Coll. Cardiol. 2006, 47:492-499.
9. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 2006, 58:342-374.
10. Segrest J.P., Harvey S.C., Zannis V. Detailed molecular model of apolipoproteins A-I on the surface of high-density lipoproteins and its functional implications. Trends Cardiovasc. Med. 2000, 10:246-252.
11. Karlsson H., Leanderson P., Tagesson C., Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:1431-1445.
12. Rosenson R.S., Brewer H.B., Ansell B., et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 2013, 128:1256-1267.
13. Rosenson R.S., Brewer H.B., Chapman M.J., et al. HDL measures, particles heterogeneity, proposed nomenclature and relation to atherosclerotic cardiovascular events. Clin. Chem. 2011, 57:392-410.
14. Rash J.M., Rothblat G.H., Sparks C.E. Lipoprotein apoliprotein synthesis by human hepatoma cells in culture. Biochim. Biophys. Acta 1981, 666:294-298.
15. Chapman M.J., Le Goff W., Guerin M., Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 2010, 31:149-164.
16. Maric J., Kiss R.S., Franklin V., Marcel Y.L. Intracellular lipidation of newly synthesized apolipoprotein A-I in primary murine hepatocytes. J. Biol. Chem. 2005, 280:39942-39949.
17. Wellington C.L., Walker E.K., Suares A., et al. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab. Invest. 2002, 82:273-283.
18. Castro G.R., Fielding C.J. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988, 27:25-29.
19. Tall A.R., Sammett D., Vita G.M., Deckelbaum R., Olivecrona T. Lipoprotein lipase enhances the cholesteryl ester transfer protein-mediated transfer of cholesteryl ester from high density lipoproteins to very low density lipoproteins. J. Biol. Chem. 1984, 259:9587-9594.
20. Savel J., Lafitte M., Pucheu Y., et al. Molecular cloning low levels of HDL-cholesterol and atherosclerosis, a variable relationship-a review of LCAT deficiency. Vasc. Health Risk Manag. 2012, 8:357-361.
21. Rousset X., Vaisman B., Amar M., Sethi A.A., Remaley A.T. Lecithin:cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 2009, 16:163-171.
22. Bowry V., Stanley K.K., Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:10316-10320.
23. Robbesyn F., Garcia V., Auge N., et al. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-KB activation in smooth muscle cells. FASEB J. 2003, 17:743-745.
24. Lee C.M., Chien C.T., Chang P.Y., et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity. Atherosclerosis 2005, 183:251-258.
25. Nicholls S.J., Dusting G.J., Cutri B., et al. Reconstituted HDL inhibits the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005, 111:1543-1550.
26. Navab M., Hama S.Y., Cooke C.J., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 2000, 41:1481-1494.
27. Navab M., Hama S.Y., Anantharamaiah G., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 2000, 41:1495-1508.
28. Greenow K., Pearce N.J., Ramji D.P. The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 2005, 83:329-342.
29. Kunitake S.T., Jarvis M.R., Hamilton R.L., Kane J.P. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:6993-6997.
30. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 1993, 35:1126-1138.
31. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J. Clin. Invest. 1998, 101:1581-1590.
32. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1451-1457.
33. James R.W., Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic. Biol. Med. 2004, 37:1986-1994.
34. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003, 107:2775-2779.
35. Six D.A., Dennis E.A. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim. Biophys. Acta 2000, 1488:1-19.
36. Karasawa K. Clinical aspects of plasma platelet activating factor-acetylhydrolase. Biochim. Biophys. Acta 2006, 1761:1359-1372.
37. Watson A.D., Navab M., Hama S.Y., et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 1995, 95:774-782.
38. Evangelou A.M. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot. Essent. Fatty Acids 1994, 50:1-28.
39. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1987-1994.
40. Calabresi L., Franceschini G., Sirtori C.R., et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem. Biophys. Res. Commun. 1997, 238:61-65.
41. Baker P.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid Res. 1999, 40:345-353.
42. Xia P., Vadas M.A., Rye K.A., Barter P.J., Gamble J.R. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway: a possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 1999, 274:33143-33147.
43. Norata G.D., Callegari E., Marchesi M., Chiesa G., Eriksson P., Catapano A.L. High-density lipoproteins induce transforming growth factor-beta 2 expression in endothelial cells. Circulation 2005, 111:2805-2811.
44. Gomaraschi M., Basilico N., Sisto F., et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim. Biophys. Acta 2005, 1736:136-143.
45. Van Lenten B.J., Navab M., Shih D., Fogelman A.M., Lusis A.J. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med. 2001, 11:155-161.
46. Navab M., Ananthramaiah G., Reddy S.T., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 2004, 45:993-1007.
47. Furnkranz A., Schober A., Bochkov V.N., et al. Oxidized phospholipids trigger atherogenic inflammation in murine arteries. Arterioscler. Thromb. Vasc. Biol. 2005, 25:633-638.
48. Theilmeier G., de Geest B., van Veldhoven P.P., et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J. 2000, 14:2032-2039.
49. Griffin J.H., Kojima K., Banka C.L., Curtiss L.K., Fernandez J.A. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. 1999, 103:219-227.
50. Mineo C., Deguchi H., Griffin J.H., Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ. Res. 2006, 98:1352-1364.
51. Suc I., Escargueil-Blanc I., Troly M., Salvayre R., Negre-Salvayre A. HDL and Apo A prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2158-2166.
52. Sugano M., Tsuchida K., Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem. Biophys. Res. Commun. 2000, 272:872-876.
53. Kwon Y.G., Min J.K., Kim K.M., Lee D.J., Billiar T.R., Kim Y.M. Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production. J. Biol. Chem. 2001, 276:10627-10633.
54. Nofer J.R., van der Giet M., Tölle M., et al. HDL induces NO dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004, 113:569-581.
55. Zhang B., Tomura H., Kuwabara A., et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 2005, 178:199-205.
56. Drew B.G., Fidge N.H., Gallon-Beaumier G., Kemp B.E., Kingwell B.A. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6999-7004.
57. Yuhanna I.S., Zhu Y., Cox B.E., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 2001, 7:853-857.
58. Norata G.D., Callegari E., Inoue H., Catapano A.L. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler. Thromb. Vasc. Biol. 2004, 24:871-877.
59. Kimura T., Sato K., Malchinkhuu E., et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1283-1288.
60. Tamama K., Tomura H., Sato K., et al. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis 2005, 178:19-23.
61. Deguchi H., Fernandez J.A., Hackeng T.M., Banka C.L., Griffin J.H. Cardiolipin is a normal component of human plasma lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1743-1748.
62. Chen L.Y., Mehta J.L. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci. 1994, 55:1815-1821.
63. Ma J., Liao X.L., Lou B., Wu M.P. Role of apolipoprotein A-I in protecting against endotoxin toxicity. Acta Biochim. Biophys. Sin. 2004, 36:419-424.
64. Pajkrt D., Doran J.E., Koster F., et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 1996, 184:1601-1608.
65. Stoll L.L., Denning G.M., Weintraub N.L. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2227-2236.
66. Yu R., Yekta B., Vakili L., et al. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr. Atheroscler. Rep. 2008, 10:171-176.
67. Shah P.K., Chyu K.Y. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc. Med. 2005, 15:291-296.
68. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fogelman A.M. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2:504-511.
69. Tölle M., Huang T., Schuchardt M., et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc. Res. 2012, 94:154-162.
70. Dullaart R.P., de Boer J.F., Annema W., Tietge U.J. The inverse relation of HDL anti-oxidative functionality with serum amyloid A is lost in metabolic syndrome. Obesity 2013, 21:361-366.
71. Drayna D., Jarnagin A.S., McLean J. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987, 327:632-634.
72. Tall A.R. Plasma lipid transfer proteins. Annu. Rev. Biochem. 1995, 64:235-257.
73. Barter P.J. CETP and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2029-2031.
74. Barter P.J., Hopkins C.J., Calver G.D. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem. J. 1982, 208:1-7.
75. Marcel Y.L., McPherson M., Hogue H., et al. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J. Clin. Invest. 1990, 85:10-17.
76. Gautier T., Masson D., de Barros J.P., et al. Human apolipoprotein CI accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J. Biol. Chem. 2000, 275:37504-37509.
77. Wang X., Driscoll D.M., Morton R.E. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J. Biol. Chem. 1999, 274:1814-1820.
78. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 1995, 15:551-561.
79. Chung B.H., Segrest J.P., Franklin F. In vitro production of beta-very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin:cholesterol acyl transferase, cholesteryl ester transfer protein and lipoprotein lipase. Atherosclerosis 1998, 141:209-225.
80. Newnham H.H., Barter P.J. Synergistic effects of lipid transfers and hepatic lipase in the formation of very small high density lipoproteins during incubation of human plasma. Biochim. Biophys. Acta 1990, 1044:57-64.
81. Liang H.Q., Rye K.A., Barter P.J. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J. Lipid Res. 1994, 35:1187-1199.
82. Rye K.A., Hime N.J., Barter P.J. Evidence that CETP-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J. Biol. Chem. 1997, 272:5953-5960.
83. Lund-Katz S., Laplaud P.M., Phillips M.C., Chapman M.J. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry 1998, 37:12867-12874.
84. Mann C.J., Yen F.T., Grant A.M., Bihain B.E. Mechanism of cholesteryl ester transfer in hypertriglyceridemia. J. Clin. Invest. 1991, 88:2059-2066.
85. Qiu X.Y., Mistry A., Ammirati M.J., et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol. 2007, 14:106-113.
86. Barter P.J., Jones M.E. Kinetic studies of the transfer of esterified cholesterol between human-plasma low and high-density lipoproteins. J. Lipid Res. 1980, 21:238-249.
87. Ihm J., Quinn D.M., Busch S.J., Chataing B., Harmony J.A. Kinetics of plasma protein-catalyzed exchange of phosphatidylcholine and cholesteryl ester between plasma lipoproteins. J. Lipid Res. 1982, 23:1328-1341.
88. Zhang L., Yan F., Zhang S., et al. Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat. Chem. Biol. 2012, 8:342-349.
89. Gomez Rosso L., Benitez M.B., Fornari M.C., Berardi V., Lynch S., Schreier L., et al. Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome. Atherosclerosis 2008, 199:415-423.
90. Coniglio R.I., Meroño T., Montiel H., et al. HOMA-IR and non-HDL-C as a predictors of high cholesterol ester transfer protein activity in patients at risk for type 2 diabetes. Clin. Biochem. 2012, 45:566-570.
91. Jonker J.T., Wang Y., de Haan W., et al. Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes. Diabetes Care 2010, 33:1625-1628.
92. Oliveira H.C., de Faria E.C. Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles. IUBMB Life 2011, 63:248-257.
93. Clark R.W., Ruggeri R.B., Cunningham D., Bamberger M.J. Description of the torcetrapib series of cholesterol ester transfer protein inhibitors, including the mechanism of action. J. Lipid Res. 2006, 47:537-552.
94. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007, 357:2109-2122.
95. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 2007, 356:1620-1630.
96. Bots M.L., Visseren F.L., Evans G.W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153-160.
97. Barter P.J. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am. J. Cardiol. 2009, 104:10E-15E.
98. Stroes E.S., Kastelein J.J., Bénardeau A., et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br. J. Pharmacol. 2009, 158:1763-1770.
99. Forrest M.J., Bloomfield D., Briscoe R.J., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 2008, 154:1465-1473.
100. Guerin M., Le Goff W., Duchene E., et al. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 2008, 28:148-154.
101. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406:203-207.
102. Niesor E.J., von der Marck E., Brousse M., Maugeais C. Inhibition of cholesteryl ester transfer protein (CETP): different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR). Atherosclerosis 2008, 199:231.
103. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159-2165.
104. Kuivenhoven J.A., de Grooth G.J., Kawamura H., et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 2005, 95:1085-1088.
105. Stein E.A., Roth E.M., Rhyne J.M., Burgess T., Kallend D., Robinson J.G. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48- week trial. Eur. Heart J. 2010, 31:480-488.
106. Ranalletta M., Bierilo K.K., Chen Y., et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 2010, 51:2739-2752.
107. Krishna R., Anderson M.S., Bergman A.J., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370:1907-1914.
108. Bloomfield D., Carlson G.L., Sapre A., et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 2009, 157:352-360.
109. Cannon C.P., Dansky H.M., Davidson M., et al. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am. Heart J. 2009, 158:513-519.
110. Cannon C.P., Shah S., Dansky H.M., et al. Determining the efficacy and tolerability investigators, safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 2010, 363:2406-2415.
111. Yvan-Charvet L., Kling J., Pagler T., et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1430-1438.
112. Gutstein D.E., Krishna R., Johns D., et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin. Pharmacol. Ther. 2012, 91:109-122.
113. Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc. Health Risk Manag. 2012, 8:323-331.
114. Cao G., Beyer T.P., Zhang Y., et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J. Lipid Res. 2011, 52:2169-2176.
115. Nicholls S.J., Brewer H.B., Kastelein J.J., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statin on HDL and LDL cholesterol. A randomized controlled trial. JAMA 2011, 306:2099-2109.
116. Day J.R., Albers J.J., Lofton-Day C.E., et al. Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J. Biol. Chem. 1994, 269:9388-9391.
117. Hailman E., Albers J.J., Wolfbauer G., Tu A.Y., Wright S.D. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J. Biol. Chem. 1996, 271:12172-12178.
118. Albers J.J., Day J.R., Wolfbauer G., Kennedy H., Vuletic S., Cheung M.C. Impact of site-specific N-glycosylation on cellular secretion, activity and specific activity of the plasma phospholipid transfer protein. Biochim. Biophys. Acta 2011, 1814:908-911.
119. Oka T., Kujiraoka T., Ito M. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J. Lipid Res. 2000, 41:1651-1657.
120. Kärkkäinen M., Oka T., Olkkonen V.M., et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J. Biol. Chem. 2002, 277:15413-15418.
121. Cheung M.C., Wolfbauer G., Albers J.J. Different phospholipid transfer protein complexes contribute to the variation in plasma PLTP specific activity. Biochim. Biophys. Acta 2011, 1811:343-347.
122. Janis M.T., Metso J., Lankinen H., et al. Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochem. Biophys. Res. Commun. 2005, 331:333-340.
123. Albers J.J., Vuletic S., Cheung M.C. Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. Biochim. Biophys. Acta 2012, 1821:345-357.
124. Tall A.R., Krumholz S., Olivecrona T., Deckelbaum R.J. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J. Lipid Res. 1985, 26:842-851.
125. Jiang X.C., Bruce C., Mar J., et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 1999, 103:907-914.
126. Jiang X.C., Tall A.R., Qin S., et al. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J. Biol. Chem. 2002, 277:31850-31856.
127. Bailey B., Ruel I., Mafinae A., et al. Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis. J. Lipid Res. 2010, 51:785-797.
128. Wolfbauer G., Albers J.J., Oram J.F. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim. Biophys. Acta 1999, 1439:65-76.
129. Vikstedt R., Metso J., Hakala J., Olkkonen V.M., Ehnholm C., Jauhiainen M. Cholesterol efflux from macrophage foam cell is enhanced by active phospholipid transfer protein through generation of two types of acceptor particles. Biochemistry 2007, 46:11979-11986.
130. Oram J.F., Wolfbauer G., Tang C., Davidson W.S., Albers J.J. An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux. J. Biol. Chem. 2008, 283:11541-11549.
131. Cheung M.C., Wolfbauer G., Deguchi H., Fernandez J.A., Griffin J.H., Albers J.J. Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology. Biochim. Biophys. Acta 2009, 1791:206-211.
132. Dullaart R.P., de Vries R., Scheek L., et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand. J. Clin. Lab. Invest. 2004, 64:205-215.
133. Murdoch S.J., Carr M.C., Hokanson J.E., Brunzell J.D., Albers J.J. PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J. Lipid Res. 2000, 41:237-244.
134. Cheung M.C., Knopp R.H., Retzlaff B., Kennedy H., Wolfbauer G., Albers J.J. Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity. Biochim. Biophys. Acta 2002, 1587:53-59.
135. Colhoun M.H., Taskinen M.R., Otvos J.D., van den Berg P., O'Connor J., van Tol A. Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 2002, 51:3300-3305.
136. Riemens S.C., van Tol A., Sluiter W.J., Dullaart R.P. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 1998, 41:929-934.
137. Kaser S., Sandhofer A., Föger B., et al. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 2001, 44:1111-1117.
138. Schlitt A., Bickel C., Thumma P., et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1857-1862.
139. Yatsuya H., Tamakoshi K., Hattori H., et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ. J. 2004, 68:11-16.
140. Cavusoglu E., Marmur J.D., Chhabra S., Chopra V., Eng C., Jiang X.C. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. Atherosclerosis 2009, 207:261-265.
141. Chen X., Sun A., Mansoor A., et al. Plasma PLTP activity is inversely associated with HDL-C levels. Nutr. Metab. 2009, 6:49-54.
142. Schgoer W., Mueller T., Jauhiainen M., et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis 2008, 196:219-226.
143. Oka T., Yamashita S., Kujiraoka T., et al. Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia. J. Lipid Res. 2002, 43:1236-1243.
144. Kostner G.M., Oetti K., Jauhiainen M., Ehnholm C., Esterbauer H., Dieplinger H. Human plasma phospholipid transfer protein accelerates exchange/transfer of alpha-tocopherol between lipoproteins and cells. Biochem. J. 1995, 305:659-667.
145. Desrumaux C., Deckert V., Athias A., et al. Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells. FASEB J. 1999, 13:883-892.
146. Yan D., Navab M., Bruce C., Fogelman A.M., Jiang X.C. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J. Lipid Res. 2004, 45:1852-1858.
147. Yang X.P., Yan D., Qiao C., et al. Increased atherosclerotic lesions in apo E mice with plasma phospholipid transfer protein overexpression. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1601-1607.
148. Klein A., Deckert V., Schneider M., et al. Alpha-tocopherol modulates phosphatidylserine externalization in erythrocytes: relevance in phospholipid transfer protein-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2160-2167.
149. Oslakovic C., Krisinger M.J., Andersson A., Jauhiainen M., Ehnholm C., Dahlbäck B. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J. Biol. Chem. 2009, 284:5896-5904.
150. Oslakovic C., Jauhiainen M., Ehnholm C., Dahlbäck B. The role of phospholipid transfer protein in lipoprotein-mediated neutralization of the procoagulant effect of anionic liposomes. J. Thromb. Haemost. 2010, 8:766-772.
151. de Vries R., Dallinga-Thie G.M., Smit A.J., Wolffenbuttel B.H., van Tol A., Dullaart R.P. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006, 49:398-404.
152. Quintão E.C., Cazita P.M. Lipid transfer proteins: past, present and perspectives. Atherosclerosis 2010, 209:1-9.
153. Thompson A., Di Angelantonio E., Sarwar N., et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008, 299:2777-2788.
154. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 2007, 356:1304-1316.
155. Ritsch A., Scharnagl H., Eller P., et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2010, 121:366-374.
156. Khera A.V., Wolfe M.L., Cannon C.P., Qin J., Rader D.J. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE-IT-TIMI 22] Study). Am. J. Cardiol. 2010, 106:451-456.
157. Vergeer M., Boekholdt M., Sandhu M.S., et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010, 122:470-477.
158. Robins S.J., Lyass A., Brocia R.W., Massaro J.M., Vasan R.S. Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. Atherosclerosis 2013, 228:230-236.
159. Franceschini G., Sirtori C.R., Capurso A., Weisgraber K.H., Mahley R.W. A-IMilano poprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an italian family. J. Clin. Invest. 1980, 66:892-900.
160. Franceschini G., Sirtori C.R., Bosisio E., et al. Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis 1985, 58:159-174.
161. Gualandri V., Orsini G.B., Cerrone A., Franceschini G., Sirtori C.R. Familial associations of lipids and lipoproteins in a highly consanguineous population: the Limone Sul Garda Study. Metabolism 1985, 34:212-221.
162. Sirtori C.R., Calabresi L., Franceschini G., et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001, 103:1949-1954.
163. Franceschini G., Calabresi L., Chiesa G., et al. Increased cholesterol efflux potential of sera from Apo A-I Milano carriers and transgenic mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1257-1262.
164. Parolini C., Chiesa G., Zhu Y., et al. Targeted replacement of mouse apolipoprotein A-I with human ApoA-I or the mutant ApoAIMilano. Evidence of APOA-IM impaired hepatic secretion. J. Biol. Chem. 2003, 278:4740-4746.
165. Parolini C., Chiesa G., Gong E., et al. Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis 2005, 183:222-229.
166. Lebherz C., Sanmiguel J., Wilson J.M., Rader D.J. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc. Diabetol. 2007, 6:6-15.
167. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 2011, 364:127-135.
168. Lo Prete A.C., Dina C.H., Azevedo C.H., et al. In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment. Lipids 2009, 44:917-924.
169. Azevedo C.H., Wajngarten M., Lo Prete A.C., Diament J., Maranhão R.C. Simultaneous transfer of cholesterol, triglycerides, and phospholipids to high-density lipoprotein in aging subjects with or without coronary artery disease. Clinics (Sao Paulo) 2011, 66:1543-1548.
170. Giribela A.H., Melo N.R., Latrilha M.C., Baracat E.C., Maranhão R.C. HDL concentration, lipid transfer to HDL, and HDL size in normolipidemic nonobese menopausal women. Int. J. Gynaecol. Obstet. 2009, 104:117-120.
171. Maranhão R.C., Freitas F.R., Strunz C.M., Santos R.D., Mansur A.J., Mansur A.P. Lipid transfers to HDL are predictors of precocious clinical coronary heart disease. Clin. Chim. Acta 2012, 413:502-505.
172. Bertato M.P., Oliveira C.P., Wajchenberg B.L., Lerario A.C., Maranhão R.C. Plasma kinetics of an LDL-like nanoemulsion and lipid transfer to HDL in subjects with glucose intolerance. Clinics (Sao Paulo) 2012, 67:347-353.
173. Casella-Filho A., Chagas A.C., Maranhão R.C., et al. Effect of exercise training on plasma levels and functional properties of high-density lipoprotein cholesterol in the metabolic syndrome. Am. J. Cardiol. 2011, 107:1168-1172.
174. Oliveira C.P., Maranhão R.C., Bertato M.P., Wajchenberg B.L., Lerario A.C. Removal from the plasma of the free and esterified forms of cholesterol and transfer of lipids to HDL in type 2 diabetes mellitus patients. Lipids Health Dis. 2012, 11:65.
175. Feitosa A.C., Feitosa-Filho G.S., Freitas F.R., Wajchenberg B.L., Maranhão R.C. Lipoprotein metabolism in patients with type 1 diabetes under intensive insulin treatment. Lipids Health Dis. 2013, 12:15.
176. Martinez L.R., Santos R.D., Miname M.H., Deus D.F., Lima E.S., Maranhão R.C. Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia. Metabolism 2013, 62:1061-1064.
177. Rocha M.P., Maranhão R.C., Seydell T.M., et al. Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome. Fertil. Steril. 2010, 93:1948-1956.
178. Sigal G.A., Medeiros-Neto G., Vinagre J.C., Diament J., Maranhão R.C. Lipid metabolism in subclinical hypothyroidism: plasma kinetics of triglyceride-rich lipoproteins and lipid transfers to high-density lipoprotein before and after levothyroxine treatment. Thyroid 2011, 21:347-353.
179. Puk C.G., Bocchi E.A., Lo Prete A.C., Ferreira S.M., Stolf N.A., Maranhão R.C. Transfer of cholesterol and other lipids from a lipid nanoemulsion to high-density lipoprotein in heart transplant patients. J. Heart Lung Transplant. 2009, 28:1075-1080.
180. Daminelli E.N., Spada C., Treitinger A., Oliveira T.V., Latrilha M.C., Maranhão R.C. Alterations in lipidtransfer to high-density lipoprotein (HDL) and activity of paraoxonase-1 in HIV+ patients. Rev. Inst. Med. Trop. Sao Paulo 2008, 50:223-227.
181. Vinagre J.C., Vinagre C.G., Pozzi F.S., Slywitch E., Maranhão R.C. Metabolism of triglyceride-rich lipoproteins and transfer of lipids to high-density lipoproteins (HDL) in vegan and omnivore subjects. Nutr. Metab. Cardiovasc. Dis. 2013, 23:61-67.
182. Gagliardi A.C., Maranhão R.C., de Sousa H.P., Schaefer E.J., Santos R.D. Effects of margarines and butter consumption on lipid profiles, inflammation markers and lipid transfer to HDL particles in free-living subjects with the metabolic syndrome. Eur. J. Clin. Nutr. 2010, 64:1141-1149.
183. Silva J.L., Vinagre C.G., Morikawa A.T., Alves M.J., Mesquita C.H., Maranhão R.C. Resistance training changes LDL metabolism in normolipidemic subjects: a study with a nanoemulsion mimetic of LDL. Atherosclerosis 2011, 219:532-537.
184. Vaisberg M., Bachi A.L., Latrilha M.C., Dioguardi G.S., Bydlowski S.P., Maranhão R.C. Lipid transfer to HDL is higher in marathon runners than in sedentary subjects, but is acutely inhibited during the run. Lipids 2012, 47:679-686.
185. Santos R.D., Hueb W., Oliveira A.A., Ramires J.A., Maranhão R.C. Plasma kinetics of a cholesterol-rich emulsion in subjects with or without coronary artery disease. J. Lipid Res. 2003, 44:464-469.
186. Couto R.D., Dallan L.A., Lisboa L.A., Mesquita C.H., Vinagre C.G., Maranhão R.C. Deposition of free cholesterol in the blood vessels of patients with coronary artery disease: a possible novel mechanism for atherogenesis. Lipids 2007, 42:411-418.
187. Sudano I., Spieker L.E., Noll G., Corti R., Weber R., Lüscher T.F. Cardiovascular disease in HIV infection. Am. Heart J. 2006, 151:1147-1155.
188. Guerin M., Le Goff W., Lassel T.S., et al. Atherogenic role of elevated CE transfer from HDL to VLDL (1) and dense LDL in type 2 diabetes: impact of the degree of hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 2001, 21:282-288.
189. Hayek T., Azrolan N., Verdery R.B., et al. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice. J. Clin. Invest. 1993, 92:1143-1152.
190. Inazu A., Brown M.L., Hesler C.B., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 1990, 323:1234-1238.